AB
ATXS

Amalgamated Bank’s Astria Therapeutics ATXS Stock Holding History

Amalgamated Bank’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,299
Closed -$17K – 1727
2025
Q4 		$17K Sell
1,299
-384
-23% -$4.59K ﹤0.01% 2176
2025
Q3 		$12K Hold
1,683
– – ﹤0.01% 2355
2025
Q2 		$9K Hold
1,683
– – ﹤0.01% 2461
2025
Q1 		$9K Hold
1,683
– – ﹤0.01% 2399
2024
Q4 		$15K Hold
1,683
– – ﹤0.01% 2228
2024
Q3 		$19K Hold
1,683
– – ﹤0.01% 2145
2024
Q2 		$15K Hold
1,683
– – ﹤0.01% 2225
2024
Q1 		$24K Sell
1,683
-1,766
-51% -$22K ﹤0.01% 2057
2023
Q4 		$26K Sell
3,449
-256
-7% -$1.42K ﹤0.01% 2526
2023
Q3 		$28K Hold
3,705
– – ﹤0.01% 2492
2023
Q2 		$31K Buy
+3,705
New +$42.8K ﹤0.01% 2507

Amalgamated Bank's ATXS Position: Q1 2026 in Review

Amalgamated Bank sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 1,299 shares — an estimated $17K sold.

Amalgamated Bank first reported a position in ATXS in Q2 2023 and held it in 11 quarters. The position peaked at $31K in Q2 2023. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

  • Amalgamated Bank reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,299 Astria Therapeutics shares in Q1 2026, an estimated $17K.
  • Amalgamated Bank first reported a position in Astria Therapeutics in Q2 2023 and held it in 11 quarters.
  • Amalgamated Bank's Astria Therapeutics position peaked at $31K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.